This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Lee's Pharmaceutical Holdings Limited
Drug Names(s): pexastimogene devacirepvec, SNG-162, JX-594, TG6006, thymidine kinase-deleted vaccinia virus plus GM-CSF
Description: Pexa-Vec/Icaritin is a fixed dose combination of Pexa-Vec(pexastimogene devacirepvec) and Icaritin.
Lee's and Shenogen
In August 2016, Lees Pharmaceutical and Shenogen Pharma Group announced a collaboration agreement to jointly develop and commercialize in China a combination product that is composed of their respective clinical compounds, Pexa-Vec and icaritin, for treatment of late stage cancers.
Partners: Shenogen Pharma Group
Pexa-Vec/Icaritin FDC News
Additional information available to subscribers only: